Bizarre Patents
An electrified table cloth for preventing crawling insects from gaining access to the consumer's food or drink.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120034265 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... | 02/09/2012 |
| 20120034264 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... | 02/09/2012 |
| 20120020997 | MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.... | 01/26/2012 |
| 20120009215 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... | 01/12/2012 |
| 20110262481 | HIGH GROWTH REASSORTANT INFLUENZA A VIRUS The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA... | 10/27/2011 |
| 20110212117 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... | 09/01/2011 |
| 20110212128 | Universal virus-like particle (VLP) influenza vaccines Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.... | 09/01/2011 |
| 20110200635 | COMBINED INFLUENZA VACCINES FOR SEASONAL AND PANDEMIC PROTECTION Current approaches to influenza vaccination focus either on seasonal strains or pandemic strains. Current seasonal vaccines typically include antigens from two influenza A strains (H1N1 and H3N2) and one influenza B strain. Current pandemic vaccines focus on H5N1 influe... | 08/18/2011 |
| 20110189230 | VACCINATION WITH MULTIPLE CLADES OF H5 INFLUENZA A VIRUS H5N1 influenza viruses isolated from animals and humans since 2003 separate into distinct clades based on hemagglutinin amino acid sequences. According to the invention, multiple clades are used in influenza immunization. Thus there is a prime-boost immunization schedul... | 08/04/2011 |
| 20110182936 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... | 07/28/2011 |
| 20110162982 | Methods for producing vaccine adjuvants An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion th... | 07/07/2011 |
| 20110142912 | NON-SPECIFIC IMMUNOSTIMULATING AGENTS The present invention relates to the use of a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.... | 06/16/2011 |
| 20110104202 | Modified Influenza Virus For Monitoring And Improving Vaccine Efficiency The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutini... | 05/05/2011 |
| 20110070263 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... | 03/24/2011 |
| 20110002960 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... | 01/06/2011 |
| 20100330118 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.... | 12/30/2010 |
| 20100247569 | Influenza A Virus Vaccines and Inhibitors The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochem... | 09/30/2010 |
| 20100233204 | Immunogenic Compositions and Methods for Treating and Preventing Animal Infections The present disclosure relates to multivalent immunogen compositions for treating or preventing diseases or disorders in canines caused by or associated with one or more of canine distemper virus, canine adenovirus (type 1 or type 2), canine parainfluenza virus, canine ... | 09/16/2010 |
| 20100221349 | NUCLEIC ACID CONSTRUCTS A nucleic acid construct comprising a chimeric promoter sequence and a cloning site for insertion of a coding sequence in operable linkage with the chimeric promoter, wherein the chimeric promoter sequence comprises: (a) a Hcmv immediate early promoter sequence; (b) exo... | 09/02/2010 |
| 20100215675 | REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND LETHALITY IN INFLUENZA The present invention provides methods of differentiating the infectivity and lethality of isolates of influenza virus and provides compounds for diagnosing, preventing, and treating outbreaks of influenza virus including compounds for diagnosing, preventing, and treati... | 08/26/2010 |
| 20100183668 | USE OF COCCIDIAN The present invention provides a novel use of coccidian, specifically relates to the use of coccidian as a vaccine live vector. The present invention further provides a live vaccine with coccidian as a vector, which is transgenic coccidian capable of expressing exogenou... | 07/22/2010 |
| 20100183667 | Vaccine Comprising an Oil in Water Emulsion Adjuvant The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5-10 mg metabolisable oil, 0.5-11 mg tocol and 0.1-4 mg... | 07/22/2010 |
| 20100178331 | PREPARATION FOR TRANSNASAL APPLICATION Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising: a fluidability-improving component comprising a first crystalline c... | 07/15/2010 |
| 20100158942 | ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also re... | 06/24/2010 |
| 20100136052 | REPLICATION DEFICIENT INFLUENZA VIRUS FOR THE EXPRESSION OF HETEROLOGOUS SEQUENCES The present invention covers a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and a heterologous sequence inserted between the splice donor sit... | 06/03/2010 |
| 20100136050 | Extracellular Matrix Materials as Vaccine Adjuvants for Diseases Associated with Infectious Pathogens or Toxins Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuv... | 06/03/2010 |
| 20100129399 | LINEAR EXPRESSION CONSTRUCTS FOR PRODUCTION OF INFLUENZA VIRUS PARTICLES The present invention provides a linear expression construct free of any conventional amplification and/or selection sequences comprising an RNA polymerase I (polI) promoter and a polI termination signal, inserted between a RNA polymerase II (polII) promoter and a polya... | 05/27/2010 |
| 20100104595 | LYOPHILIZED PREPARATION COMPRISING INFLUENZA VACCINE, AND METHOD FOR PREPARATION THEREOF The present invention aims to provide a freeze-dried preparation in which the influenza vaccine exhibits improved stability. A freeze-dried preparation in which the influenza vaccine exhibits significantly improved stability can be obtained... | 04/29/2010 |
| 20100086485 | INFLUENZA VACCINE The present invention relates to a live-attenuated bacterial cell comprising a heterologous nucleotide sequence encoding at least one influenza virus antigen in operative linkage to an expression system.... | 04/08/2010 |
| 20100068223 | Storage of Influenza Vaccines Without Refrigeration Antigens from individual influenza virus strains are not refrigerated before being combined to make multivalent influenza virus vaccines. Moreover, influenza vaccines are not refrigerated between packaging and administration. Thus the need for refrigeration is minimized... | 03/18/2010 |
| 20100055129 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF INDENTIFIYING AGENTS THAT MODULATE MYC Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune respons... | 03/04/2010 |
| 20100047275 | PEPTIDE SEQUENCES AND COMPOSITIONS Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-6, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homolog... | 02/25/2010 |
| 20090324639 | COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND ALLERGIC IMMUNITY Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for e... | 12/31/2009 |
| 20090324640 | NEURAMINIDASE-DEFICIENT LIVE INFLUENZA VACCINES Attenuated, neuraminidase deficient influenza virus, and compositions and methods to prepare that virus, are provided.... | 12/31/2009 |
| 20090311288 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS The invention proyides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are nov... | 12/17/2009 |
| 20090304729 | CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by tre... | 12/10/2009 |
| 20090304739 | INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the inv... | 12/10/2009 |
| 20090304735 | Immunogenic Compositions The present invention relates to an immunogenic composition for raising an immune response to an antigen, the composition comprising the antigen and a targeting moiety specific for lymph-resident dendritic cells. Use of the immunogenic composition in a vaccine and metho... | 12/10/2009 |
| 20090280142 | METHODS OF DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS A method of detecting osteoporosis in a mammalian is disclosed herein which includes:
| 11/12/2009 |
| 20090252762 | NOVEL PROTEOSOME-LIPOSACCHARIDE VACCINE ADJUVANT An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic composi... | 10/08/2009 |
